File downloaded on 2026-11-08
Source URL: https://medicines.health.europa.eu/veterinary/en/600000044985

ZURITOL 50 MG/ML ORAL SUSPENSION FOR PIGS

Ima dovoljenje za promet

- Toltrazuril

Informacije o zdravilu

Ime zdravila:
ZURITOL 50 MG/ML ORAL SUSPENSION FOR PIGS

Učinkovina:
Na voljo samo v English

Ciljne živalske vrste:
Na voljo samo v Bulgarian Spanish Czech Danish German Estonian Greek English French Italian Latvian Lithuanian Hungarian Dutch Romanian Finnish Swedish Icelandic Norwegian

Pot uporabe:
Peroralna uporaba

Podatki o zdravilu

Učinkovina / Jakost:
Na voljo samo v English
50.00 milligram(s) / 1.00 millilitre(s)

Farmacevtska oblika:

Peroralna suspenzija

Karenca glede na pot uporabe:

Peroralna uporaba:

- **Pig (piglet)**
  - Meat and offal. 77 day

Anatomsko-terapevtsko-kemična veterinarska oznaka klasifikacija zdravil, ki se uporabljajo v veterini (ATCvet):

QP51BC01

Pravni status za dobavo/izdajo zdravila:

Zdravilo, ki se izdaja na veterinarski recept

Status dovoljenja za promet z zdravilom:

Valid

Ima dovoljenje za promet v:

Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian

Opis ovojnine zdravila:

Na voljo samo v English

Na voljo samo v English

Dodatne informacije

Vrsta dovoljenja:

Na voljo samo v English French Croatian Italian Latvian Finnish Swedish Icelandic Norwegian

Pravna podlaga za izdajo dovoljenja za promet z zdravilom:

Na voljo samo v English Italian Latvian Norwegian

Imetnik dovoljenja za promet z zdravilom:

Laboratorios Calier S.A.

Datum dovoljenja za promet z zdravilom:
9/11/2013

Proizvodna mesta, odgovorna za sproščanje serij:
Laboratorios Calier S.A.

Pristojni organ:
Federal Office Of Consumer Protection And Food Safety

Številka dovoljenja za promet z zdravilom:
401886.00.00

Datum spremembe statusa dovoljenja za promet:
14/02/2019

Referenčna država članica:
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian

Številka postopka:
FR/V/0257/001

Zadevne države članice:
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian
Na voljo samo v Spanish Czech German Estonian Greek English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian
Na voljo samo v Spanish German Estonian English French Italian Dutch Portuguese Slovak Finnish Swedish Icelandic Norwegian
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian

Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian
Na voljo samo v Spanish Czech German Estonian English French Croatian Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian

---

Za poročila o domnevnih neželenih učinkih zdravil za uporabo v veterinaski medicini obiščite stran: www.adrreports.eu/vet

Dokumenti

Combined File of all Documents

Ta dokument ne obstaja v tem jeziku (slovenščina). Lahko ga najdete spodaj v drugem jeziku.

eu-puar-frv0257001-mr-rpe_119-en.pdf